title: HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab.
abstract: BACKGROUND
  Trastuzumab treatment improves survival of HER2-positive primary breast cancer. HER2 staining intensity varies widely in HER2-positive tumours.
  
  
  METHODS
  We investigated whether differences in immunohistochemical (IHC) staining intensity for HER2 in HER2-positive tumors (IHC 3+ or FISH ratio ≥2.0) was associated with prognosis or benefit from trastuzumab treatment in patients randomized to 1 year or no trastuzumab in the HERceptin Adjuvant (HERA) trial. Median follow-up was 2 years. The nested case-control analysis, included 425 patients (cases) with a disease-free survival (DFS) event and two matched controls (no DFS event) per case. Tissue sections stained for HER2 were assessed for HER2 staining intensity by image analysis.
  
  
  RESULTS
  HER2 staining intensity varied widely and correlated with HER2 gene copy number (Spearman, r = 0.498, P < 0.001) or less closely with HER2/CEP17 FISH ratio (r = 0.396, P < 0.001). We found no significant difference in DFS in the observation arm according to staining intensity (odds ratio [OR] change per 10 unit change in intensity: 1.015, 95% confidence interval [CI] 0.930-1.108) and no impact of staining intensity on benefit derived from 1-year trastuzumab (OR: 1.017, 95% CI 0.925-1.120).
  
  
  CONCLUSIONS
  Variability in HER2 staining in HER2-positive tumours has no role in clinical management with adjuvant trastuzumab.
  NCT00045032.
authors.affiliation: Academic Department of Biochemistry, Royal Marsden NHS Trust, London.
authors.forename: L
authors.initials: L
authors.lastname: Zabaglo
authors.forename: O
authors.initials: O
authors.lastname: Stoss
authors.forename: J
authors.initials: J
authors.lastname: Rüschoff
authors.forename: D
authors.initials: D
authors.lastname: Zielinski
authors.forename: J
authors.initials: J
authors.lastname: Salter
authors.forename: M
authors.initials: M
authors.lastname: Arfi
authors.forename: I
authors.initials: I
authors.lastname: Bradbury
authors.forename: U
authors.initials: U
authors.lastname: Dafni
authors.forename: M
authors.initials: M
authors.lastname: Piccart-Gebhart
authors.forename: M
authors.initials: M
authors.lastname: Procter
authors.forename: M
authors.initials: M
authors.lastname: Dowsett
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D016022:Case-Control Studies; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008875:Middle Aged; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000302:isolation & purification* / Q000378:metabolism; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human
keywords: HER2; HERA; IHC intensity; Trastuzumab; breast cancer